| A Short Biotech & Genetics Industry Glossary | i |
| Introduction | 1 |
| How to Use This Book | 3 |
| Chapter 1: Major Trends Affecting the Biotech & Genetics Industry | 7 |
| 1) The State of the Biotechnology Industry Today | 7 |
| 2) A Short History of Biotechnology | 11 |
| 3) Ethanol Production Soared, But a Market Glut May Slow Expansion | 12 |
| 4) New Money Pours into Biotech Firms/Mergers and Acquisitions Surge Ahead | 14 |
| 5) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms | 15 |
| 6) From India to Singapore to Australia, Nations Compete Fiercely in Biotech Development | 15 |
| 7) Gene Therapies and Patients' Genetic Profiles Promise a Personalized Approach to Medicine | 17 |
| 8) New Kinase Inhibitors Are Breakthrough Drugs for Cancer Treatment - Many More Will Follow | 19 |
| 9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Soar | 19 |
| 10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age | 21 |
| 11) Biogenerics (Follow-on Biologics) are in Limbo in the U.S. | 22 |
| 12) Breakthrough Drug Delivery Systems Evolve | 23 |
| 13) Stem Cells - Controversy in the U.S. Threatens to Leave America Far Behind in the Research Race | 24 |
| 14) Stem Cell Funding Trickles in the U.S. at the Federal Level While a Few States Create Funding of Their Own | 25 |
| 15) Stem Cells -Therapeutic Cloning Techniques Advance | 26 |
| 16) Stem Cells - A New Era of Regenerative Medicine Looms | 27 |
| 17) Nanotechnology Converges with Biotech | 29 |
| 18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise | 30 |
| 19) Focus on Vaccines | 32 |
| 20) Ethical Issues Abound | 33 |
| 21) Technology Discussion - Genomics | 33 |
| 22) Technology Discussion - Proteomics | 34 |
| 23) Technology Discussion - Microarrays | 34 |
| 24) Technology Discussion - DNA Chips | 34 |
| 25) Technology Discussion - SNPs ("Snips") | 35 |
| 26) Technology Discussion - Combinatorial Chemistry | 35 |
| 27) Technology Discussion - Synthetic Biology | 35 |
| 28) Technology Discussion - Recombinant DNA | 36 |
| 29) Technology Discussion - Polymerase Chain Reaction (PCR) | 36 |
| Chapter 2: Biotech & Genetics Industry Statistics | 37 |
| Biotech Industry Overview | 38 |
| Global Biotechnology at a Glance: 2007 | 39 |
| Growth in Global Biotechnology: 2006-2007 | 40 |
| 20 Largest Global Pharmaceutical Companies: 2006-2007 | 41 |
| Global Area of Biotech Crops by Country: 2007 | 42 |
| Biotechnology Financing, U.S., Europe & Canada: 2006-2007 | 43 |
| U.S. Biotechnology at a Glance: 2006-2007 | 44 |
| Quarterly Breakdown of Biotechnology Financings, U.S. & Canada: 2007 | 45 |
| Ernst & Young Survival Index, U.S. & Canadian Biotechnology Companies: 2006-2007 | 46 |
| Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1970-2007 | 47 |
| Sales by Geographic Area, PhRMA Member Companies: 2006 | 48 |
| Domestic Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1970-2007 | 49 |
| Domestic Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2006 | 50 |
| R&D By Global Geographic Area, PhRMA Member Companies: 2006 | 51 |
| Biologics & Biotechnology R&D, PhRMA Member Companies: 2006 | 52 |
| R&D as a Percentage of U.S. Biopharmaceutical Sales, PhRMA Member Companies: 1970-2007 | 53 |
| U.S. Exports & Imports of Pharmaceutical Products: 2002-1st Quarter 2008 | 54 |
| Summary of Value of U.S. Shipments of Pharmaceutical Preparations, Except Biologicals: 2003-2007 | 55 |
| Value of U.S. Shipments of Pharmaceutical Preparations, Except Biologicals, Detailed: 2007 | 56 |
| Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2006-2008 | 61 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2007-2009 | 62 |
| National Health Expenditure Amounts by Type of Expenditure, U.S.: Selected Calendar Years, 2002-2017 | 63 |
| Prescription Drug Expenditures, U.S.: 1965-2016 | 64 |
| U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: Selected Calendar Years, 2002-2017 | 66 |
| The U.S. Drug Discovery & Approval Process | 67 |
| U.S. FDA Approval Times for New Drugs: 1993-2007 | 68 |
| U.S. FDA Approval Times for New Molecular Entities (NMEs): 1993-2007 | 69 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2007 | 70 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2006 | 71 |
| Plant-Derived Pharmaceuticals for the Treatment of Human Diseases that are in the Pipeline for Commercialization: 2007 | 72 |
| Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2007 | 73 |
| Domestic Biopharmaceutical R&D Scientific, Professional & Technical Personnel by Function, PhRMA Member Companies: 2006 | 74 |
| Chapter 3: Important Biotech & Genetics Industry Contacts | 75 |
| (Addresses, Phone Numbers and Internet Sites) | |
| Chapter 4: THE BIOTECH 400: | |
| Who They Are and How They Were Chosen | 109 |
| Industry List, With Codes | 110 |
| Index of Rankings Within Industry Groups | 112 |
| Alphabetical Index | 122 |
| Index of Headquarters Location by U.S. State | 126 |
| Index of Non-U.S. Headquarters Location by Country | 130 |
| Index by Regions of the U.S. Where the Firms Have Locations | 132 |
| Index by Firms with Operations Outside the U.S. | 138 |
| Individual Profiles on Each of THE BIOTECH 400 | 141 |
| Additional Indexes | |
| Index of Hot Spots for Advancement for Women/Minorities | 548 |
| Index by Subsidiaries, Brand Names and Selected Affiliations | 550 |